<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-id journal-id-type="iso-abbrev">Pediatr Rheumatol Online J</journal-id><journal-title-group><journal-title>Pediatric Rheumatology Online Journal</journal-title></journal-title-group><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4044571</article-id><article-id pub-id-type="publisher-id">1546-0096-11-S2-O19</article-id><article-id pub-id-type="doi">10.1186/1546-0096-11-S2-O19</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>PReS-FINAL-2184: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Ruperto</surname><given-names>N</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Pistorio</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Knupp Feitosa de Oliveira</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Cuttica</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Ravelli</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Fischbach</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Magnusson</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Avcin</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Brochard</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Corona</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Couillault</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Dressler</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Gerloni</surname><given-names>V</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Sterba</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>Zulian</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A16"><name><surname>Apaz</surname><given-names>MT</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A17"><name><surname>Cespedes-Cruz</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A18"><name><surname>Cimaz</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A19"><name><surname>Bracaglia</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A20"><name><surname>Joos</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A21"><name><surname>Quartier</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A22"><name><surname>Russo</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A23"><name><surname>Tardieu</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A24"><name><surname>Wulffraat</surname><given-names>N</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A25"><name><surname>Angioloni</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A26"><name><surname>Martini</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Istituto G. Gaslini, Genoa, Italy</aff><aff id="I2"><label>2</label>PRINTO, Genoa, Italy</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2013</year></pub-date><volume>11</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">Proceedings of 20th Pediatric Rheumatology European Society (PReS) Congress</named-content><named-content content-type="supplement-sponsor">The publication charges for this supplement were funded by the PReS 2013 congress.</named-content></supplement><fpage>O19</fpage><lpage>O19</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Ruperto et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Ruperto et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.ped-rheum.com/content/11/S2/O19"/><conference><conf-date>25-29 September 2013</conf-date><conf-name>20th Pediatric Rheumatology European Society (PReS) Congress</conf-name><conf-loc>Ljubljana, Slovenia</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Data regarding the safety and efficacy of treatment regimens for juvenile dermatomyositis (JDM) tends to be from anecdotal, small, uncontrolled, non-randomized case series.</p></sec><sec><title>Objectives</title><p>To find out the treatment regimen associated with the lowest occurrence of flare and the lowest drug related toxicity in juvenile dermatomyositis (JDM).</p></sec><sec sec-type="methods"><title>Methods</title><p>Children with newly diagnosed JDM were randomized in an open fashion to receive: prednisone (PDN) versus PDN plus methotrexate (MTX) versus PDN plus Cyclosporine A (CASA). Primary outcome measures after 6 months of treatment: response rate according to the Paediatric Rheumatology International Trials Organisation (PRINTO) provisional definition of improvement. Primary outcome measures after 24 months of treatment: a) time to inactive disease; b) time to major therapeutic changes because of inefficacy/flare/adverse events; time to flare.</p></sec><sec sec-type="results"><title>Results</title><p>139 randomized patients were included in the efficacy dataset. There were 82 females (59%) with a median age at onset of 7.4 years (1st-3rd quartiles <bold>4.4-10.6</bold>) and a median disease duration of 2.8 months (1.3-5.3). Frequency of response at 6 months was for 24/47 (51%) for PDN, 32/46 (70%) for PDN+CSA and 32/46 (70%) for PDN+MTX (p 0.032).</p><p>There was a statistically significant difference for inactive disease/clinical remission between group 3 (PDN+MTX) versus group 2 (PDN +CSA) and 1 (PDN) combined (Log-Rank test p 0.021 and p 0.012, respectively) and in the time to major therapeutic change (defined as the addition of CSA or MTX or any other disease-modifying anti-rheumatic drug) between group 1 (PDN) versus group 2 (PDN+CSA) and 3 (PDN+MTX) combined (p = 0.009). No statistical significant differences in time to flare (Log-rank test; p = 0.39). The safety analysis showed that group 2 (PDN+CSA) had greater number of adverse events (AE) when compared to group 1 (PDN) and 3 (PDN+MTX) (p = 0.005). Similarly there was a statistically significant increase in the frequency of AE in group 2 (PDN+CSA) when compared to Group 1 (PDN) and 3 (PDN+MTX) in several systems (skin and subcutaneous tissues, gastrointestinal, and general disorders. Infections/infestations) and others (hypertrichosis, hirsutism/hair growth, and abdominal pain). There were no statistically significant differences in serious AE among the 3 groups (p 0.17). There were no deaths.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Combined therapy with PDN and either CSA or MTX was more effective than with PDN alone. However the safety profile favors the combination with MTX with respect to CSA.</p></sec><sec><title>Disclosure of interest</title><p>None declared.</p></sec></body></article>